文献速递头痛与眩晕

乌布吉泮在偏头痛前驱期给药对患者报告结局的影响:随机PRODROME试验结果

Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial.
PubMed 文献 · Neurology · 2024-08-28

PRODROME是一项多中心、随机、双盲、安慰剂对照交叉试验,纳入每月2-8次偏头痛发作的成人,比较前驱期使用乌布吉泮100 mg与安慰剂对患者报告结局的影响。结果显示,乌布吉泮在24小时内正常功能能力、活动受限减少及满意度方面均优于安慰剂。

要点

  • 前驱期使用乌布吉泮100 mg较安慰剂显著提高24小时内正常功能能力(OR 1.66)。
  • 给药后2小时,乌布吉泮组报告「无残疾、能正常功能」的比例更高(OR 1.76)。
  • 乌布吉泮组在8小时和24小时满意度均高于安慰剂(OR分别为2.37和2.32)。

核心结论

  • 前驱期使用乌布吉泮100 mg与安慰剂相比,与24小时内正常功能能力显著提高、活动受限减少及对研究药物满意度更高相关。

研究设计与样本

  • PRODROME为多中心、随机、双盲、安慰剂对照交叉试验,纳入每月2-8次偏头痛发作伴中重度头痛的成人。
  • 518例随机参与者中,477例构成改良意向治疗人群;参与者治疗2次符合条件的 prodrome 事件。
  • 随机分配至治疗序列A(安慰剂后乌布吉泮100 mg)或序列B(乌布吉泮100 mg后安慰剂)。

主要发现

  • 乌布吉泮100 mg组24小时内正常功能能力显著高于安慰剂组(OR 1.66,95% CI 1.40-1.96;p < 0.0001)。
  • 给药后2小时,乌布吉泮组报告「无残疾、能正常功能」比例高于安慰剂组(OR 1.76,95% CI 1.32-2.35;名义p = 0.0001)。
  • 乌布吉泮组24小时内活动受限减少优于安慰剂组(OR 2.07,95% CI 1.61-2.67;名义p < 0.0001)。
  • 给药后8小时和24小时,乌布吉泮组「满意」或「非常满意」率高于安慰剂组(8小时:OR 2.37,95% CI 1.78-3.15;名义p < 0.0001;24小时:OR 2.32,95% CI 1.78-3.02;名义p < 0.0001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Ubrogepant is a calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine. The PRODROME trial previously demonstrated that ubrogepant treatment during prodrome prevents the onset of moderate or severe headache. In this analysis of the PRODROME trial, the benefits of ubrogepant treatment during the prodrome on patient-reported outcomes (PROs) are evaluated. METHODS: PRODROME was a multicenter, randomized, double-blind, placebo-controlled, crossover trial that enrolled adults who experienced 2-8 migraine attacks per month with moderate-severe headache pain. Eligible participants treated 2 qualifying prodrome events, defined as a migraine attack with prodromal symptoms when the participant was confident a headache would follow within 1-6 hours. Participants were randomized to treatment sequence A (placebo then ubrogepant 100 mg) or sequence B (ubrogepant 100 mg then placebo). This analysis evaluated the ability to function normally over 24 hours (secondary end point) and at specific time points after dose (additional end point). Other PRO end points included activity limitation over 24 hours and satisfaction with study medication at 8 and 24 hours. RESULTS: Of 518 randomized participants, 477 comprised the modified intent-to-treat population. After treatment of qualifying prodrome events, a significantly greater ability to function normally over 24 hours was observed for participants after treatment with ubrogepant 100 mg compared with placebo (odds ratio [OR] 1.66, 95% CI 1.40-1.96; p < 0.0001). As early as 2 hours after dose, a greater proportion of ubrogepant-treated participants reported "no disability, able to function normally" compared with placebo (OR 1.76, 95% CI 1.32-2.35; nominal p = 0.0001). Ubrogepant administered during the prodrome was also associated with a greater reduction in activity limitations over 24 hours after dose (OR 2.07, 95% CI 1.61-2.67; nominal p < 0.0001). At 8 and 24 hours after dose, rates of being "satisfied" or "extremely satisfied" were greater for ubrogepant than for placebo (8 hours: OR 2.37, 95% CI 1.78-3.15; nominal p < 0.0001; 24 hours: OR 2.32, 95% CI 1.78-3.02; nominal p < 0.0001). DISCUSSION: Ubrogepant 100 mg administered during the prodrome was associated with significantly greater ability to function normally, greater reduction in activity limitations over 24 hours, and greater satisfaction with study medication, compared with placebo. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT04492020. Submitted: July 27, 2020; first patient enrolled: August 21, 2020. clinicaltrials.gov/ct2/show/NCT04492020. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that taking ubrogepant 100 mg during a migraine prodrome allows more patients to function normally over the next 24 hours.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lipton RB, Harriott AM, Ma JY, et al. Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial. Neurology. 2024. PMID: 39197113. doi:10.1212/WNL.0000000000209745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。